The product is only FDA u003cemu003eregistered u003c/emu003eas a wellness device, which does not mean approval for safety or proven effectiveness
Saxenda was one of the earliest GLP-1 medications specifically indicated for weight loss, and although newer agents now offer greater potency, Saxenda remains a valuable option for patients who prefer daily dosing, respond well to its metabolic effects, or have insurance coverage that favors this formulation
At higher doses, the glucagon receptor activation may actually help preserve lean mass through increased protein turnover and growth hormone modulation, but the data on this is still emerging
By product type, the injectable GLP-1 analogues segment held the biggest market share of 70% in 2025
While long-term safety and cardiovascular outcome data remain under investigation, current clinical results position retatrutide as a potential paradigm shift among next-generation incretin-based medications
95% CI, 2.52 to 7.86) [73]
